This week's Brexit downsides: half a billion in extra costs to import food, the collapse of trade talks with Canada and more.

As obvious as it is to see the decline in the number of clinical trials in the UK, the reasons behind this trend are as complicated to ascertain. Fiona Maini, Principal - Global Compliance and Strategy at Medidata Solutions, thinks the issue is multifaced with Brexit playing a part in this.

Bloc plans to bulk-buy key drugs for all 27 countries, potentially leaving Britain ‘behind in the queue’. / “Europe is securing access to key drugs and vaccines as a single region, with huge influence and buying power. As a result of Brexit the UK is now isolated from this system, so our drug supplies could be at risk in the future,” said Dr Andrew Hill, an expert on the pharmaceutical trade.

Health Secretary Matt Hancock has claimed Brexit allowed the UK to approve a Covid vaccine more quickly than other European Union (EU) countries.

Helmuth Porschen ponders the fate of UKCA and wonders why the government can’t persuade the rest of the world to adopt British standards.

The hot rhetoric of ‘taking back control’ of our borders is being replaced by cold reality.

"If you will do this damn silly thing, don't do it in this damn silly way. This bill will come back to haunt this gov't, in the same way so many other mistakes, harrumphed to the rafters in this House, have."

An organisation which represents medicines wholesalers says supplying Northern Ireland remains "challenging, problematic and inefficient".

There are growing post-Brexit differences between which medicines are approved for use in Northern Ireland and the rest of the UK, research from a health think tank indicates.

Are you a quality manager for a small medical device start-up looking to expand into global markets? Or maybe you are a seasoned device manufacturer preparing to once again traverse quality regulations to deliver a new product to the European market?

As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

BREXIT is causing “damage across the board” to UK science, including missing out on more than £1 billion in funding, campaigners have warned.

A new EU directive is allowing member states to remove the charge for ‘supply and installation of solar panels’.

There are a number of measures that the UK Government must take in order to address the challenges of leaving the EU's single market.

Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

The government and its supporters are beginning to claim 'benefits' of being outside the European Union some of which were always available to EU member states or, in other cases, are not benefits at all.

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions.

This note summarises the evidence so far of the impacts on Brexit on Scotland. It sets out early evidence related to areas such as trade, the workforce and EU programmes.

Dr Philippa Whitford, MP and eminent breast cancer surgeon, shares her concerns for the future of our NHS following Brexit. Recorded in front of a live audience at Arran High School Theatre on Friday 13th September 2019.

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.

Relocation to Amsterdam will give better access to European markets ‘regardless of Brexit outcome’.